Intracranial atherosclerosis

The Lancet

Volumn 383, Issue 9921, 2014, Pages 984-998

  Qureshi, Adnan I ^a   Caplan, Louis R ^b  

^a Zeenat Qureshi Stroke Institute and CentraCare Health   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM ANTAGONIST; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NADROPARIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; THROMBIN INHIBITOR; WARFARIN;

AGING; ANGIOPLASTY; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; BLOOD PRESSURE; BRAIN ANGIOGRAPHY; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CATHETER; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; COLLATERAL CIRCULATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STENT; THROMBOEMBOLISM; TRANSCRANIAL DOPPLER; TRANSIENT ISCHEMIC ATTACK;

ALGORITHMS; ANGIOPLASTY; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MENTAL DISORDERS; RISK FACTORS; STENTS; STROKE;

EID: 84896142952     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61088-0     Document Type: Conference Paper

References (173)

1. Resch JA, Loewenson RB, Baker AB. Physical factors in the pathogenesis of cerebral atherosclerosis. Stroke 1970; 1: 77-85.
2. Mathur KS, Kashyap SK, Kumar V. Correlation of the extent and severity of atherosclerosis in the coronary and cerebral arteries. Circulation 1963; 27: 929-34.
3. Manzano JJ, De Silva DA, Pascual JL, Chang HM, Wong MC, Chen CP. Associations of ankle-brachial index (ABI) with cerebral arterial disease and vascular events following ischemic stroke. Atherosclerosis 2012; 223: 219-22.
4. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 2009; 8: 345-54.
5. Suri MF, Johnston SC. Epidemiology of intracranial stenosis. J Neuroimaging 2009; 19 (suppl 1): S11-16.
6. Bos D, van der Rijk MJ, Geeraedts TE, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke 2012; 43: 1878-84.
7. Wong KS, Ng PW, Tang A, Liu R, Yeung V, Tomlinson B. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients. Neurology 2007; 68: 2035-38.
8. Huang HW, Guo MH, Lin RJ, et al. Prevalence and risk factors of middle cerebral artery stenosis in asymptomatic residents in Rongqi County, Guangdong. Cerebrovasc Dis 2007; 24: 111-15.
9. Suri MF, Georgiadis AL, Tariq N, Vazquez G, Qureshi N, Qureshi AI. Estimated prevalence of acoustic cranial windows and intracranial stenosis in the US elderly population: ultrasound screening in adults for intracranial disease study. Neuroepidemiology 2011; 37: 64-71.
10. Hass WK, Fields WS, North RR, Kircheff II, Chase NE, Bauer RB. Joint study of extracranial arterial occlusion. II. Arteriography, techniques, sites, and complications. JAMA 1968; 203: 961-68.
11. Feldmann E, Daneault N, Kwan E, et al. Chinese-white diff erences in the distribution of occlusive cerebrovascular disease. Neurology 1990; 40: 1541-45.
12. Kieff er SA, Takeya Y, Resch JA, Amplatz K. Racial diff erences in cerebrovascular disease. Angiographic evaluation of Japanese and American populations. Am J Roentgenol Radium Ther Nucl Med 1967; 101: 94-99.
13. Leung SY, Ng TH, Yuen ST, Lauder IJ, Ho FC. Pattern of cerebral atherosclerosis in Hong Kong Chinese. Severity in intracranial and extracranial vessels. Stroke 1993; 24: 779-86.
14. McGarry P, Solberg LA, Guzman MA, Strong JP. Cerebral atherosclerosis in New Orleans. Comparisons of lesions by age, sex, and race. Lab Invest 1985; 52: 533-39.
15. Solberg LA, McGarry PA. Cerebral atherosclerosis in Negroes and Caucasians. Atherosclerosis 1972; 16: 141-54.
16. Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986; 17: 648-55.
17. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005; 111: 1327-31.
18. Thomas GN, Lin JW, Lam WW, et al. Increasing severity of cardiovascular risk factors with increasing middle cerebral artery stenotic involvement in type 2 diabetic Chinese patients with asymptomatic cerebrovascular disease. Diabetes Care 2004; 27: 1121-26.
19. Uehara T, Tabuchi M, Mori E. Frequency and clinical correlates of occlusive lesions of cerebral arteries in Japanese patients without stroke. Evaluation by MR angiography. Cerebrovasc Dis 1998; 8: 267-72.
20. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic diff erences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57: 1101-07.
21. Waddy SP, Cotsonis G, Lynn MJ, et al. Racial diff erences in vascular risk factors and outcomes of patients with intracranial atherosclerotic arterial stenosis. Stroke 2009; 40: 719-25.
22. Kuller L, Reisler DM. An explanation for variations in distribution of stroke and arteriosclerotic heart disease among populations and racial groups. Am J Epidemiol 1971; 93: 1-9.
23. Puddu P, Puddu GM, Bastagli L, Massarelli G, Muscari A. Coronary and cerebrovascular atherosclerosis: two aspects of the same disease or two diff erent pathologies? Arch Gerontol Geriatr 1995; 20: 15-22.
24. Kramer H, Han C, Post W, et al. Racial/ethnic diff erences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens 2004; 17: 963-70.
25. People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China. Baseline report from the P.R.C.-U.S.A. Collaborative Study. Circulation 1992; 85: 1083-96.
26. Stevens J, Truesdale KP, Katz EG, Cai J. Impact of body mass index on incident hypertension and diabetes in Chinese Asians, American Whites, and American Blacks: the People's Republic of China Study and the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2008; 167: 1365-74.
27. Velican C, Velican D. Atherosclerotic involvement of human intracranial arteries with special reference to intimal necrosis. Atherosclerosis 1982; 43: 59-69.
28. Stehbens WE. Cerebral atherosclerosis. Intimal proliferation and atherosclerosis in the cerebral arteries. Arch Pathol 1975; 99: 582-91.
29. Baker AB, Iannone A. Cerebrovascular disease. I. The large arteries of the circle of Willis. Neurology 1959; 9: 321-32.
30. Velican D, Anghelescu M, Petrescu C, Velican C. Method dependent limits in a study on the natural history of coronary and cerebral atherosclerosis. Med Interne 1982; 20: 215-29.
31. Takaba M, Endo S, Kurimoto M, Kuwayama N, Nishijima M, Takaku A. Vasa vasorum of the intracranial arteries. Acta Neurochir (Wien) 1998; 140: 411-16.
32. Yanai T, Masegi T, Ueda K, et al. Vascular mineralization in the monkey brain. Vet Pathol 1994; 31: 546-52.
33. Chen XY, Wong KS, Lam WW, Zhao HL, Ng HK. Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study. Cerebrovasc Dis 2008; 25: 74-80.
34. Labadzhyan A, Csiba L, Narula N, Zhou J, Narula J, Fisher M. Histopathologic evaluation of basilar artery atherosclerosis. J Neurol Sci 2011; 307: 97-99.
35. Tulamo R, Frosen J, Paetau A, et al. Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation. Am J Pathol 2010; 177: 3224-32.
36. Sun R, Xiao L, Duan S. High expression of ubiquitin conjugates and NF-?B in unstable human intracranial atherosclerotic plaques. J Cell Physiol 2012; 227: 784-88.
37. Ma suoka T, Hayashi N, Hori E, Kuwayama N, Ohtani O, Endo S. Distribution of internal elastic lamina and external elastic lamina in the internal carotid artery: possible relationship with atherosclerosis. Neurol Med Chir (Tokyo) 2010; 50: 179-82.
38. Ba e H-J, Lee J, Park J-M, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis 2007; 24: 355-60.
39. Ue hara T, Tabuchi M, Mori E. Risk factors for occlusive lesions of intracranial arteries in stroke-free Japanese. Eur J Neurol 2005; 12: 218-22.
40. Ts ivgoulis G, Vadikolias K, Heliopoulos I, et al. Prevalence of symptomatic intracranial atherosclerosis in caucasians: a prospective, multicenter, transcranial Doppler study. J Neuroimaging 2012; published online July 20. DOI:0.1111/j.1552-6569.2012.00707.x.
41. Ov biagele B, Saver JL, Lynn MJ, Chimowitz M, and the WASID Study Group. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology 2006; 66: 1344-49.
42. Pa rk JH, Kwon HM, Roh JK. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis. Eur J Neurol 2007; 14: 379-86.
43. Ba ng OY, Kim JW, Lee JH, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005; 65: 296-98.
44. Lo pez-Cancio E, Galan A, Dorado L, et al. Biological signatures of asymptomatic extra-and intracranial atherosclerosis: the Barcelona-AsIA (Asymptomatic Intracranial Atherosclerosis) study. Stroke 2012; 43: 2712-19.
45. Kim JS, Nah HW, Park SM, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease. Stroke 2012; 43: 3313-18.
46. Zhan g J, Li Y, Wang Y, et al. Arterial stiff ness and asymptomatic intracranial large arterial stenosis and calcifi cation in hypertensive chinese. Am J Hypertens 2011; 24: 304-09.
47. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke 2003; 34: 2475-81.
48. Sacc o RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke 1998; 29: 380-87.
49. Kim BJ, Lee SH, Kang BS, Yoon BW, Roh JK. Diabetes increases large artery diseases, but not small artery diseases in the brain. J Neurol 2008; 255: 1176-81.
50. Mazi ghi M, Labreuche J, Gongora-Rivera F, Duyckaerts C, Hauw JJ, Amarenco P. Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke 2008; 39: 1142-47.
51. Holm an RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
52. Boyl e PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007; (suppl 2): S12-S17.
53. More no PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-300.
54. Ois A, Gomis M, Rodriguez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008; 39: 1717-21.
55. Min W K, Kim YS, Kim JY, Park SP, Suh CK. Atherothrombotic cerebellar infarction: vascular lesion-MRI correlation of 31 cases. Stroke 1999; 30: 2376-81.
56. Siddi qui FM, Hassan AE, Tariq N, et al. Endovascular management of symptomatic extracranial stenosis associated with secondary intracranial tandem stenosis. A multicenter review. J Neuroimaging 2012; 22: 243-48.
57. Kim Y D, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fi brillation. Stroke 2011; 42: 930-34.
58. Wong KS, Huang YN, Gao S, Lam WW, Chan YL, Kay R. Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998; 50: 812-13.
59. Wong KS, Li H, Chan YL, et al. Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke 2000; 31: 2641-47.
60. Man B L, Fu YP, Chan YY, et al. Lesion patterns and stroke mechanisms in concurrent atherosclerosis of intracranial and extracranial vessels. Stroke 2009; 40: 3211-15.
61. Chen H, Hong H, Liu D, et al. Lesion patterns and mechanism of cerebral infarction caused by severe atherosclerotic intracranial internal carotid artery stenosis. J Neurol Sci 2011; 307: 79-85.
62. Lee D K, Kim JS, Kwon SU, Yoo SH, Kang DW. Lesion patterns and stroke mechanism in atherosclerotic middle cerebral artery disease: early diff usion-weighted imaging study. Stroke 2005; 36: 2583-88.
63. Mull M, Schwarz M, Thron A. Cerebral hemispheric low-fl ow infarcts in arterial occlusive disease. Lesion patterns and angiomorphological conditions. Stroke 1997; 28: 118-23.
64. Narit omi H, Sawada T, Kuriyama Y, Kinugawa H, Kaneko T, Takamiya M. Eff ect of chronic middle cerebral artery stenosis on the local cerebral hemodynamics. Stroke 1985; 16: 214-19.
65. Kang DW, Kwon SU, Yoo SH, et al. Early recurrent ischemic lesions on diff usion-weighted imaging in symptomatic intracranial atherosclerosis. Arch Neurol 2007; 64: 50-54.
66. Cho K H, Kang DW, Kwon SU, Kim JS. Location of single subcortical infarction due to middle cerebral artery atherosclerosis: proximal versus distal arterial stenosis. J Neurol Neurosurg Psychiatry 2009; 80: 48-52.
67. Khan A, Kasner SE, Lynn MJ, Chimowitz MI, and the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke 2012; 43: 1230-33.
68. Yoon BW, Bae HJ, Kang DW, et al. Intracranial cerebral artery disease as a risk factor for central nervous system complications of coronary artery bypass graft surgery. Stroke 2001; 32: 94-99.
69. Lee E J, Choi KH, Ryu JS, et al. Stroke risk after coronary artery bypass graft surgery and extent of cerebral artery atherosclerosis. J Am Coll Cardiol 2011; 57: 1811-18.
70. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68: 231-40.
71. Tronc oso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Eff ect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008; 64: 168-76.
72. Andra de SP, Brucki SM, Bueno OF, Siqueira Neto JI. Neuropsychological performance in patients with subcortical stroke. Arq Neuropsiquiatr 2012; 70: 341-47.
73. Jokin en H, Gouw AA, Madureira S, et al, and the LADIS Study Group. Incident lacunes infl uence cognitive decline: the LADIS study. Neurology 2011; 76: 1872-78.
74. Saczy nski JS, Sigurdsson S, Jonsdottir MK, et al. Cerebral infarcts and cognitive performance: importance of location and number of infarcts. Stroke 2009; 40: 677-82.
75. Lee J S, Im DS, An YS, Hong JM, Gwag BJ, Joo IS. Chronic cerebral hypoperfusion in a mouse model of Alzheimer's disease: an additional contributing factor of cognitive impairment. Neurosci Lett 2011; 489: 84-88.
76. Mok V C, Lam WW, Fan YH, et al. Eff ects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 2009; 256: 750-57.
77. Bos D , Vernooij MW, Elias-Smale SE, et al. Atherosclerotic calcifi cation relates to cognitive function and to brain changes on magnetic resonance imaging. Alzheimers Dement 2012; (suppl): S104-S11.
78. Erten-Lyons DSL, Mattek N, Dodge H, et al. Neuropathologic basis of white matter hyperintensity. Neurology 2013; 80 (Meeting Abstracts 1): S44.001.
79. Verno oij MW, Ikram MA, Vrooman HA, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry 2009; 66: 545-53.
80. Mofta khar R, Turk AS, Niemann DB, et al. Eff ects of carotid or vertebrobasilar stent placement on cerebral perfusion and cognition. AJNR Am J Neuroradiol 2005; 26: 1772-80.
81. Zhiyo u C, Yong Y, Shanquan S, et al. Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res 2009; 34: 1226-35.
82. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64: 494-500.
83. Licht-Strunk E, Bremmer MA, van Marwijk HW, et al. Depression in older persons with versus without vascular disease in the open population: similar depressive symptom patterns, more disability. J Aff ect Disord 2004; 83: 155-60.
84. Naard ing P, Tiemeier H, Breteler MM, et al. Clinically defi ned vascular depression in the general population. Psychol Med 2007; 37: 383-92.
85. Grool AM, van der Graaf Y, Mali WP, Geerlings MI, and the SMART Study Group. Location of cerebrovascular and degenerative changes, depressive symptoms and cognitive functioning in later life: the SMART-Medea study. J Neurol Neurosurg Psychiatry 2011; 82: 1093-100.
86. Barne s DE, Yaff e K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: diff erential eff ects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012; 69: 493-98.
87. Hou W H, Liu X, Duan YY, et al. Evaluation of transcranial color-coded duplex sonography for cerebral artery stenosis or occlusion. Cerebrovasc Dis 2009; 27: 479-84.
88. Hirai T, Korogi Y, Ono K, et al. Prospective evaluation of suspected stenoocclusive disease of the intracranial artery: combined MR angiography and CT angiography compared with digital subtraction angiography. AJNR Am J Neuroradiol 2002; 23: 93-101.
89. Skutta B, Furst G, Eilers J, Ferbert A, Kuhn FP. Intracranial stenoocclusive disease: double-detector helical CT angiography versus digital subtraction angiography. AJNR Am J Neuroradiol 1999; 20: 791-99.
90. Feldmann E, Wilterdink JL, Kosinski A, et al, and the Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) Trial Investigators. The stroke outcomes and neuroimaging of intracranial atherosclerosis (SONIA) trial. Neurology 2007; 68: 2099-106.
91. Bash S, Villablanca JP, Jahan R, et al. Intracranial vascular stenosis and occlusive disease: evaluation with CT angiography, MR angiography, and digital subtraction angiography. AJNR Am J Neuroradiol 2005; 26: 1012-21.
92. Chimowitz MI, Lynn MJ, Derdeyn CP, et al, and the SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003.
93. Choi HY, Ye BS, Ahn SH, et al. Characteristics and the fate of intraluminal thrombus of the intracranial and extracranial cerebral arteries in acute ischemic stroke patients. Eur Neurol 2009; 62: 72-78.
94. Cho AH, Kwon SU, Kim JS, Kang DW. Evaluation of early dynamic changes of intracranial arterial occlusion is useful for stroke etiology diagnosis. J Neurol Sci 2012; 312: 127-30.
95. Hassan AE, Rostambeigi N, Chaudhry SA, et al. Combination of noninvasive neurovascular imaging modalities in stroke patients: patterns of use and impact on need for digital subtraction angiography. J Stroke Cerebrovasc Dis 2012; published online May 10. DOI:10.1016/j.jstrokecerebrovasdis.2012.03.020.
96. Nguyen-Huynh MN, Wintermark M, English J, et al. How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke 2008; 39: 1184-88.
97. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000; 21: 643-46.
98. Liebeskind DS, Cotsonis GA, Saver JL, Lynn MJ, Cloft HJ, Chimowitz MI, and the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Investigators. Collateral circulation in symptomatic intracranial atherosclerosis. J Cereb Blood Flow Metab 2011; 31: 1293-301.
99. Liebeskind DS, Cotsonis GA, Saver JL, et al, and the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Investigators. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. Ann Neurol 2011; 69: 963-74.
100. Kasner SE, Chimowitz MI, Lynn MJ, et al, and the Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113: 555-63.
101. Lau AY, Wong EH, Wong A, Mok VC, Leung TW, Wong KS. Signifi cance of good collateral compensation in symptomatic intracranial atherosclerosis. Cerebrovasc Dis 2012; 33: 517-24.
102. Kim HJ, Kim TW, Ryu SY, et al. Acetazolamide-challenged perfusion magnetic resonance imaging for assessment of cerebrovascular reserve capacity in patients with symptomatic middle cerebral artery stenosis: comparison with technetium-99mhexamethylpropyleneamine oxime single-photon emission computed tomography. Clin Imaging 2011; 35: 413-20.
103. Komotar RJ, Starke RM, Otten ML, et al. The role of indirect extracranial-intracranial bypass in the treatment of symptomatic intracranial atheroocclusive disease. J Neurosurg 2009; 110: 896-904.
104. Aoki S, Shirouzu I, Sasaki Y, et al. Enhancement of the intracranial arterial wall at MR imaging: relationship to cerebral atherosclerosis. Radiology 1995; 194: 477-81.
105. Zacharatos H, Hassan AE, Qureshi AI. Intravascular ultrasound: principles and cerebrovascular applications. AJNR Am J Neuroradiol 2010; 31: 586-97.
106. Ravalli S, LiMandri G, Di Tullio MR, et al. Intravascular ultrasound imaging of human cerebral arteries. J Neuroimaging 1996; 6: 71-75.
107. Xu WH, Li ML, Gao S, et al. Plaque distribution of stenotic middle cerebral artery and its clinical relevance. Stroke 2011; 42: 2957-59.
108. Ryu CW, Jahng GH, Kim EJ, Choi WS, Yang DM. High resolution wall and lumen MRI of the middle cerebral arteries at 3 tesla. Cerebrovasc Dis 2009; 27: 433-42.
109. Chung GH, Kwak HS, Hwang SB, Jin GY. High resolution MR imaging in patients with symptomatic middle cerebral artery stenosis. Eur J Radiol 2012; 81: 4069-74.
110. Xu WH, Li ML, Gao S, et al. Middle cerebral artery intraplaque hemorrhage: prevalence and clinical relevance. Ann Neurol 2012; 71: 195-98.
111. Vergouwen MD, Silver FL, Mandell DM, Mikulis DJ, Swartz RH. Eccentric narrowing and enhancement of symptomatic middle cerebral artery stenoses in patients with recent ischemic stroke. Arch Neurol 2011; 68: 338-42.
112. Diethrich EB, Pauliina Margolis M, Reid DB, et al. Virtual histology intravascular ultrasound assessment of carotid artery disease: the Carotid Artery Plaque Virtual Histology Evaluation (CAPITAL) study. J Endovasc Ther 2007; 14: 676-86.
113. Hallevi H, Chernyshev OY, El Khoury R, et al. Intracranial atherosclerosis is associated with progression of neurological defi cit in subcortical stroke. Cerebrovasc Dis 2012; 33: 64-68.
114. Qureshi AI, Ziai WC, Yahia AM, et al. Stroke-free survival and its determinants in patients with symptomatic vertebrobasilar stenosis: a multicenter study. Neurosurgery 2003; 52: 1033-39, discussion 1039-40.
115. Kozak O, Tariq N, Suri MF, Taylor RA, Qureshi AI. High risk of recurrent ischemic events among patients with deferred intracranial angioplasty and stent placement for symptomatic intracranial atherosclerosis. Neurosurgery 2011; 69: 334-42, discussion 342-43.
116. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, and the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-16.
117. Wong KS, Chen C, Ng PW, et al, and the FISS-tris Study Investigators. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007; 6: 407-13.
118. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, and the ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115-24.
119. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
120. Sacco RL, Diener HC, Yusuf S, et al, and the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
121. Mazighi M, Tanasescu R, Ducrocq X, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006; 66: 1187-91.
122. Wong KS, Li H. Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke 2003; 34: 2361-66.
123. Kwon SU, Hong KS, Kang DW, et al. Effi cacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011; 42: 2883-90.
124. Gao S, Wong KS, Hansberg T, Lam WW, Droste DW, Ringelstein EB. Microembolic signal predicts recurrent cerebral ischemic events in acute stroke patients with middle cerebral artery stenosis. Stroke 2004; 35: 2832-36.
125. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000; 55: 490-97.
126. Turan TN, Maidan L, Cotsonis G, et al, and the Warfarin-Aspirin Symptomatic Intracranial Disease Investigators. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. Stroke 2009; 40: 505-09.
127. Georgiadis AL, Cordina SM, Vazquez G, et al. Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22: 100-06.
128. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in fi rst-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003; 34: 2463-68.
129. Arenillas JF, Massot A, Alvarez-Sabin J, et al. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009; 28: 95-102.
130. Nahab F, Cotsonis G, Lynn M, et al, and the WASID Study Group. Prevalence and prognosis of coexistent asymptomatic intracranial stenosis. Stroke 2008; 39: 1039-41.
131. Kremer C, Schaettin T, Georgiadis D, Baumgartner RW. Prognosis of asymptomatic stenosis of the middle cerebral artery. J Neurol Neurosurg Psychiatry 2004; 75: 1300-03.
132. Kern R, Steinke W, Daff ertshofer M, Prager R, Hennerici M. Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology 2005; 65: 859-64.
133. Mok VC, Lam WW, Chen XY, et al. Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study. Cerebrovasc Dis 2009; 28: 18-25.
134. Thomas GN, Chen XY, Lin JW, et al. Middle cerebral artery stenosis increased the risk of vascular disease mortality among type 2 diabetic patients. Cerebrovasc Dis 2008; 25: 261-67.
135. Furie KL, Kasner SE, Adams RJ, et al, and the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-76.
136. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2010. CNS Neurosci Ther 2012; 18: 93-101.
137. European Stroke Organisation (ESO) Executive Committee, and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
138. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-92.
139. Adams RJ, Chimowitz MI, Alpert JS, et al, and the Stroke Council and the Council on Clinical Cardiology of the American Heart Association, and the American Stroke Association. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientifi c statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003; 108: 1278-90.
140. FDA revises safety information and limits use of Stryker Wingspan brain stent system. 2012. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm314845.htm Accessed April 22, 2013.
141. Halkes PH, Gray LJ, Bath PM, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008; 79: 1218-23.
142. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative effi cacy and safety of new oral anticoagulants in patients with atrial fi brillation. Circ Cardiovasc Qual Outcomes 2012; 5: 480-86.
143. Douen AG, Medic S, Sabih M, Pageau N, Shuaib A. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse eff ects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis 2008; 17: 356-59.
144. Lokk J. Dipyridamole-associated headache in stroke patients- interindividual diff erences? Eur Neurol 2009; 62: 109-13.
145. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A, and the European/Australasian Stroke Prevention in Reversible Ischaemia Trial Study Group. Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 2009; 80: 437-39.
146. The CLAIR Study Investigators. The eff ectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study. Int J Stroke 2012; published online Aug 7. DOI:10.1111/j.1747-4949.2012.00828.x.
147. Wong KS, Chen C, Fu J, et al, and the CLAIR study investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489-97.
148. Turan TN, Lynn MJ, Nizam A, et al, and the SAMMPRIS Investigators. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes 2012; 5: e51-60.
149. Amarenco P, Goldstein LB, Szarek M, et al, and the SPARCL Investigators. Eff ects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: 3198-204.
150. Fu JH, Mok V, Lam W, et al. Eff ects of statins on progression of subclinical brain infarct. Cerebrovasc Dis 2010; 30: 51-56.
151. Rothwell PM, Giles MF, Chandratheva A, et al, and the Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Eff ect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective populationbased sequential comparison. Lancet 2007; 370: 1432-42.
152. Lavallée PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and eff ects. Lancet Neurol 2007; 6: 953-60.
153. M eseguer E, Lavallée PC, Mazighi M, et al. Yield of systematic transcranial Doppler in patients with transient ischemic attack. Ann Neurol 2010; 68: 9-17.
154. Ma n BL, Fu YP, Chan YY, et al. Long-term outcomes of ischemic stroke patients with concurrent intracranial and extracranial stenoses and ischemic heart disease. Cerebrovasc Dis 2010; 29: 236-41.
155. Ar enillas JF, Candell-Riera J, Romero-Farina G, et al. Silent myocardial ischemia in patients with symptomatic intracranial atherosclerosis: associated factors. Stroke 2005; 36: 1201-06.
156. Ho shino A, Nakamura T, Enomoto S, et al. Clinical utility of evaluating intracranial artery stenosis and silent brain infarction to predict the presence of subclinical coronary artery disease in ischemic stroke patients. Intern Med 2008; 47: 1775-81.
157. Yo o J, Yang JH, Choi BW, et al. The frequency and risk of preclinical coronary artery disease detected using multichannel cardiac computed tomography in patients with ischemic stroke. Cerebrovasc Dis 2012; 33: 286-94.
158. Qu reshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004; 363: 804-13.
159. Fi orella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007; 38: 881-87.
160. Za idat OO, Klucznik R, Alexander MJ, et al, and the NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008; 70: 1518-24.
161. Mi ao Z, Jiang L, Wu H, et al. Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population. Stroke 2012; 43: 3284-90.
162. Qu reshi AI, Al-Senani FM, Husain S, et al. Intracranial angioplasty and stent placement after stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial: present state and future considerations. J Neuroimaging 2012; 22: 1-13.
163. Sidd iq F, Chaudhry SA, Khatri R, et al. Rate of post-procedural stroke and death in SAMMPRIS trial eligible patients treated with intracranial angioplasty and/or stent placement in practice. Neurosurgery 2012; 71: 68-73.
164. Qure shi AI, Siddiq F, Majidi M, Rodriguez GJ, Suri MFK. A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis. J Vasc Interv Neurol (in press).
165. Leif er D, Bravata DM, Connors JJ 3rd, et al, and the American Heart Association Special Writing Group of the Stroke Council, and the Atherosclerotic Peripheral Vascular Disease Working Group, and the Council on Cardiovascular Surgery and Anesthesia, and the Council on Cardiovascular Nursing. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to Brain Attack Coalition comprehensive stroke center recommendations: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 849-77.
166. Aren illas JF, Molina CA, Montaner J, Abilleira S, González- Sánchez MA, Alvarez-Sabín J. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke 2001; 32: 2898-904.
167. Kwon SU , Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005; 36: 782-86.
168. Kim DE, Kim JY, Jeong SW, et al. Association between changes in lipid profi les and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study. Stroke 2012; 43: 1824-30.
169. The EC/ IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985; 313: 1191-200.
170. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP, and the COSS Investigators. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011; 306: 1983-92.
171. Han JH, Leung TW, Lam WW, et al. Preliminary fi ndings of external counterpulsation for ischemic stroke patient with large artery occlusive disease. Stroke 2008; 39: 1340-43.
172. Lin W, Xiong L, Han J, et al. External counterpulsation augments blood pressure and cerebral fl ow velocities in ischemic stroke patients with cerebral intracranial large artery occlusive disease. Stroke 2012; 43: 3007-11.
173. Arenill as JF, Alvarez-Sabín J, Montaner J, et al. Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 2005; 36: 92-97.